Your browser doesn't support javascript.
loading
A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria.
Höglinger, Günter U; Adler, Charles H; Berg, Daniela; Klein, Christine; Outeiro, Tiago F; Poewe, Werner; Postuma, Ronald; Stoessl, A Jon; Lang, Anthony E.
Affiliation
  • Höglinger GU; Department of Neurology, University Hospital, Ludwig-Maximilians-University (LMU) and German Center for Neurodegenerative Diseases, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
  • Adler CH; Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ, USA.
  • Berg D; Christian Albrechts University and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Klein C; Institute of Neurogenetics, University of Lübeck and University Hospital Schleswig-Holstein, Campus Lübeck, Lüebeck, Germany.
  • Outeiro TF; Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, Göttingen, Germany; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Poewe W; Medical University Innsbruck, Innsbruck, Austria.
  • Postuma R; Department of Neurology, McGill University, Montreal Neurological Institute, Montreal, QC, Canada.
  • Stoessl AJ; Pacific Parkinson's Research Centre and Parkinson's Foundation Centre of Excellence, University of British Columbia, BC, Canada.
  • Lang AE; University Health Network's Krembil Brain Institute, Edmond J Safra Program in Parkinson's Disease and the Rossy PSP Centre, Toronto Western Hospital, Toronto, ON, Canada. Electronic address: anthony.lang@uhnresearch.ca.
Lancet Neurol ; 23(2): 191-204, 2024 Feb.
Article in En | MEDLINE | ID: mdl-38267191
ABSTRACT
With the hope that disease-modifying treatments could target the molecular basis of Parkinson's disease, even before the onset of symptoms, we propose a biologically based classification. Our classification acknowledges the complexity and heterogeneity of the disease by use of a three-component system (SynNeurGe) presence or absence of pathological α-synuclein (S) in tissues or CSF; evidence of underlying neurodegeneration (N) defined by neuroimaging procedures; and documentation of pathogenic gene variants (G) that cause or strongly predispose to Parkinson's disease. These three components are linked to a clinical component (C), defined either by a single high-specificity clinical feature or by multiple lower-specificity clinical features. The use of a biological classification will enable advances in both basic and clinical research, and move the field closer to the precision medicine required to develop disease-modifying therapies. We emphasise the initial application of these criteria exclusively for research. We acknowledge its ethical implications, its limitations, and the need for prospective validation in future studies.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease Type of study: Diagnostic_studies / Prognostic_studies Aspects: Ethics Limits: Humans Language: En Journal: Lancet Neurol Journal subject: NEUROLOGIA Year: 2024 Document type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease Type of study: Diagnostic_studies / Prognostic_studies Aspects: Ethics Limits: Humans Language: En Journal: Lancet Neurol Journal subject: NEUROLOGIA Year: 2024 Document type: Article Affiliation country: Germany